for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Idorsia: Neurocrine Biosciences Exercises Option To License Idorsia's Novel Treatment For Rare Pediatric Epilepsy

May 12 (Reuters) - Idorsia Ltd:

* NEUROCRINE BIOSCIENCES EXERCISES OPTION TO LICENSE IDORSIA’S NOVEL TREATMENT FOR RARE PEDIATRIC EPILEPSY

* IDORSIA RECEIVES A $45 MILLION UPFRONT PAYMENT IN CASH.

* WILL ALSO BE ENTITLED TO POTENTIAL DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS UP TO $365 MILLION AND TIERED ROYALTIES ON NET SALES Source text for Eikon: Further company coverage: (Gdansk Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up